tiprankstipranks
Corbus Pharmaceuticals price target raised to $80 from $60 at Oppenheimer
PremiumThe FlyCorbus Pharmaceuticals price target raised to $80 from $60 at Oppenheimer
1M ago
SYS6002 (CRB-701) A Next-Generation Nectin-4 Targeting Antibody Drug Conjugate Continues to Demonstrate Encouraging Safety and Efficacy Observed in Patients with Nectin-4 Positive Tumors in a Clinical Update Presented at ASCO 2024
PremiumPress Releases
SYS6002 (CRB-701) A Next-Generation Nectin-4 Targeting Antibody Drug Conjugate Continues to Demonstrate Encouraging Safety and Efficacy Observed in Patients with Nectin-4 Positive Tumors in a Clinical Update Presented at ASCO 2024
1M ago
Corbus Pharmaceuticals updated Phase 1 data for SYS-6002 to be presented at ASCO
PremiumThe Fly
Corbus Pharmaceuticals updated Phase 1 data for SYS-6002 to be presented at ASCO
1M ago
Corbus Pharmaceuticals Financial Performance Update Insights
PremiumCompany AnnouncementsCorbus Pharmaceuticals Financial Performance Update Insights
2M ago
Corbus Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update
PremiumPress Releases
Corbus Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update
2M ago
Corbus Pharmaceuticals reports Q1 EPS (83c) vs ($4.24) last year
PremiumThe Fly
Corbus Pharmaceuticals reports Q1 EPS (83c) vs ($4.24) last year
2M ago
Corbus Pharmaceuticals management to meet with Oppenheimer
PremiumThe FlyCorbus Pharmaceuticals management to meet with Oppenheimer
3M ago
Corbus announces dosing of first patient in Phase 1 trial of CRB-701
PremiumThe Fly
Corbus announces dosing of first patient in Phase 1 trial of CRB-701
3M ago
Corbus Pharmaceuticals management to meet with Oppenheimer
PremiumThe Fly
Corbus Pharmaceuticals management to meet with Oppenheimer
3M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100